Evaluation of Nootropic activity of newly synthesized n14 & n15 Phenothiazine derivatives

Objective: The present study aimed at evaluating the newly synthesized novel phenothiazine derivative (N14&N15) for memory enhancing activity in scopolamine and diazepam induced amnesic rodents using cook’s pole climbing, elevated plus maze and passive avoidance paradigm
Background: N14 and N15 are newly synthesized novel phenothiazine derivatives with substitution at N-10 position, which resembles with dopamine structure, having dopaminergic receptor agonist activity. Phenothiazines are reported to have anti-psychotic, anti-convulsant activity.
Methods: Memory enhancing activity of newly synthesized novel phenothiazine derivative (at 100, 200, and 400 mg/kg b.w.p.o.) was evaluated by both exteroceptive (cook’s pole climbing, elevated plus maze, and passive avoidance paradigm) and interceptive behaviour models (diazepam induced amnesia). Derivative was administered for 7 days at the dose of 100,200 and 400 mg/kg b.w.to rodents in cook’s pole climbing, elevated plus maze, and passive avoidance paradigm. Scopolamine (0.3 mg/kg b.w.i.p.) and Diazepam (1mg/kg b.w.i.p.) were used to induce amnesia and Piracetam (100mg/kg b.w.i.p.) served as reference standard and different parameter were assessed.
Results: Newly synthesized novel phenothiazine derivative at all doses of (100,200 and 400 mg/kg, p.o.) produced significant memory enhancing activity when evaluated by cook’s pole climbing, elevated plus maze and passive avoidance paradigm models. Treatment with novel phenothiazine derivative at all doses also improved learning and memory in normal rodents.
Conclusion: The memory enhancing activity of the derivative attributed to dopaminergic receptor agonist activity, which would have been afforded by the active constituents present in the synthesized derivative. Thus, the findings of the present study reveal the nootropic activity of newly synthesized novel phenothiazine derivative. It can be utilized in treating diseases with memory deficits like senile dementia, schizophrenia and Alzheimer’s disease.